Pages that link to "Q26747753"
Jump to navigation
Jump to search
The following pages link to Idelalisib for the treatment of indolent non-Hodgkin lymphoma: a review of its clinical potential (Q26747753):
Displaying 8 items.
- Future therapeutic targets in rheumatoid arthritis? (Q33841419) (← links)
- Primary mucosa-associated lymphoid tissue lymphoma of the liver: A report of two cases and review of the literature (Q37628526) (← links)
- New targeted therapies for malignant lymphoma based on molecular heterogeneity (Q38787141) (← links)
- Medication-associated gastrointestinal tract injury (Q39108620) (← links)
- Profile of venetoclax and its potential in the context of treatment of relapsed or refractory chronic lymphocytic leukemia (Q39145934) (← links)
- Idelalisib promotes Bim-dependent apoptosis through AKT/FoxO3a in hepatocellular carcinoma (Q58733788) (← links)
- Management of psoriasis-like rash associated with idelalisib monotherapy in a patient with refractory follicular lymphoma: a case report (Q89863810) (← links)
- Overview of Current Targeted Anti-Cancer Drugs for Therapy in Onco-Hematology (Q92258777) (← links)